Antisense Pharma Announces Closing of 16.5 Million Euro Financing
Regensburg, Germany. Antisense Pharma announced that it has successfully raised 10 million EUR within the second closing of its current expansion financing, now totalling to 16.5 million EUR. Investors in this second closing are the Global Chance Fund, Global Asset Fund and INOVA AG. The previous closing included investments from Global Chance Fund, S-Refit AG, Technologie-Beteiligungsfonds Bayern, as well as private investors.
Dr. Reimar Schlingensiepen, COO said, "We are very pleased to have completed now these two closings of our expansion financing. The excellent progress in our drug development impressed the existing and new investors and led to one of the biggest European financing rounds in the biopharmaceutical sector in 2003/2004."
Antisense Pharma GmbH intends to use the proceeds to continue the internal R&D programs and clinical development of drug candidates focusing on malignant tumors. Data from preclinical and clinical studies of the Company's most advanced anti-tumor agents, AP 12009 and AP 11014, have been presented at this years 95th Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.
Other news from the department business & finance
